Table 1 Patient demographics and immunosuppressive and antibiotic regimens
RTX (n = 21) | nRTX (n = 9) | p-value | |
|---|---|---|---|
Age, years | 56 ± 16.0 | 62 ± 20 | 0.39 |
Sex | |||
Male | 13 | 3 | 0.24 |
Female | 8 | 6 | 0.24 |
AKI stage | |||
Stage 1 | 9 | 3 | 0.70 |
Stage 2 | 11 | 3 | 0.44 |
Stage 3 | 1 | 3 | 0.07 |
sCr (mg/dL) | 3.0 ± 1.8 | 4.1 ± 3.9 | 0.29 |
BUN (mg/dL) | 46.0 ± 20.7 | 57.8 ± 35.2 | 0.26 |
Median time after RTX (month) | 5 | N/A | |
Immunosuppression | |||
TAC + mycophenolate+steroids | 16 | 0 | |
TAC + steroids | 1 | 0 | |
CYA + mycophenolate+steroids | 1 | 0 | |
CYA + mycophenolate | 1 | 0 | |
TAC + azathioprine+steroids | 1 | 0 | |
Sirolimus+mycophenolate+steroids | 1 | 0 | |
Antibioticsa | |||
Beta-lactam + beta-lactamase inhibitor | 3 | 0 | 0.53 |
Piperacillin/tazobactam | 5 | 1 | 0.64 |
Cephalosporin | 4 | 0 | 0.29 |
Metronidazole | 2 | 0 | 1 |
Fluoroquinolone | 0 | 1 | 0.3 |